dMed Biopharmaceutical

dMed Biopharmaceutical, founded in 2016, is a global clinical research service provider partnering with biopharmaceutical innovators. They deliver professional expertise and agile capabilities for complex trials. With over two decades of experience, dMed offers flexible, patient-centered solutions ensuring high-quality data delivery while reducing risks. The company focuses on aligning with client objectives to provide actionable insights for future clinical research advancements.

dMed Biopharmaceutical maintains a significant global presence, reaching patient populations across more than 40 countries to facilitate innovative breakthroughs. Employing between 500 and 1,000 professionals, they leverage expertise to support diverse clinical research needs. Their agile capabilities and patient-centric approach are key to managing complex trials efficiently. For insights into the individuals driving these efforts, one can explore Meet dMed Biopharmaceutical's team. This team's collective experience is instrumental in navigating global clinical trials and ensuring successful outcomes for partners.

dMed Biopharmaceutical generates substantial revenue, reported at $202.5M, indicating significant market presence. The company has a robust funding history, including a $100M Series C in December 2020, a $50M Series B in October 2019, and an $8M Series A in December 2016. This financial backing supports its mission to advance biopharmaceutical innovation. Key competitors include Celerion and Worldwide Clinical Trials. Interested parties can Explore financial highlights for a deeper dive into their financial performance and investment rounds.